Searched for
EQUILLIUM
U.S. stock futures today in the red as Dow, S&P 500, Nasdaq fall ahead of pivotal inflation report — Tesla, AMD, Apple, Nvidia lead market movers- Biocon starts clinical study to evaluate efficacy of Itolizumab
- Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGI
- Biocon Q2 results: Net profit drops 22% on higher R&D cost; revenue jumps 10%Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosimilar and research services busine...23 Oct, 2020, 09.57 AM IST
- Biocon extends licensing pact with Equillium for itolizumabItolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand n...12 Dec, 2019, 08.13 PM IST
- Biocon Q2 net profit at Rs 216 croreConsolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration.23 Oct, 2019, 08.21 PM IST
Load More
